- Home
- EMBC vs EOSE Comparison
EMBC vs EOSE Comparison
Compare EMBC & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMBC
- EOSE
- Stock Information
- Founded
- EMBC 1924
- EOSE 2008
- Country
- EMBC United States
- EOSE United States
- Employees
- EMBC N/A
- EOSE N/A
- Industry
- EMBC Medical/Dental Instruments
- EOSE Industrial Machinery/Components
- Sector
- EMBC Health Care
- EOSE Miscellaneous
- Exchange
- EMBC Nasdaq
- EOSE Nasdaq
- Market Cap
- EMBC 716.2M
- EOSE N/A
- IPO Year
- EMBC N/A
- EOSE N/A
- Fundamental
- Price
- EMBC $13.30
- EOSE $6.00
- Analyst Decision
- EMBC Hold
- EOSE Buy
- Analyst Count
- EMBC 3
- EOSE 6
- Target Price
- EMBC $17.67
- EOSE $6.08
- AVG Volume (30 Days)
- EMBC 423.5K
- EOSE 7.6M
- Earning Date
- EMBC 05-09-2025
- EOSE 05-06-2025
- Dividend Yield
- EMBC 4.51%
- EOSE N/A
- EPS Growth
- EMBC 2.96
- EOSE N/A
- EPS
- EMBC 0.99
- EOSE N/A
- Revenue
- EMBC $1,107,700,000.00
- EOSE $19,462,000.00
- Revenue This Year
- EMBC N/A
- EOSE $992.02
- Revenue Next Year
- EMBC $0.99
- EOSE $177.46
- P/E Ratio
- EMBC $13.44
- EOSE N/A
- Revenue Growth
- EMBC N/A
- EOSE 37.60
- 52 Week Low
- EMBC $10.12
- EOSE $0.62
- 52 Week High
- EMBC $21.48
- EOSE $6.89
- Technical
- Relative Strength Index (RSI)
- EMBC 60.26
- EOSE 62.52
- Support Level
- EMBC $12.08
- EOSE $4.86
- Resistance Level
- EMBC $12.76
- EOSE $6.89
- Average True Range (ATR)
- EMBC 0.50
- EOSE 0.41
- MACD
- EMBC 0.20
- EOSE 0.11
- Stochastic Oscillator
- EMBC 94.27
- EOSE 64.11
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.